This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Aquavit Pharmaceuticals Forms Alliance Partnership With Accelrys

NEW YORK, Sept. 21, 2012 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a leader in scientific innovation lifecycle management software, have formed an alliance partnership towards the development of Aquavit's PITO-001 and MAV-403 products.  The partner agreement was signed on September 12, 2012.  Under the terms of the partnership, Aquavit will utilize the scientifically aware Accelrys Enterprise Platform to develop advanced medical software for cutting-edge personalized medicine.

"It is an exciting opportunity for both companies.  As a leading global provider of enterprise scientific informatics software, Accelrys is the ideal partner to accelerate achievement of Aquavit's vision.  Having our products powered by the Accelrys Enterprise Platform will support our market leading science," said Sobin Chang, Aquavit's Chief Executive Officer.

"We are pleased to be partnering with Aquavit Pharmaceuticals to help accelerate the development of innovative personalized treatments," said Sanjay Gupta, Vice President of Corporate Development at Accelrys.  "The Accelrys Enterprise Platform will advance these initiatives by providing unparalleled capabilities in managing end-to-end scientific workflows to achieve better outcomes." 

This partnership will be led by Thomas S. Benjamin, Vice President of Technology at Aquavit Pharmaceuticals.  Mr. Benjamin's award winning research has appeared in The New York Times and The Wall Street Journal.  Mr. Benjamin said, "We aim to break new ground with the first-of-a-kind systems in our product lines.  We are thrilled to be integrating the powerful Accelrys Enterprise Platform into the development of our next-generation medical technologies."

About Aquavit Pharmaceuticals, Inc.Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices, and personalized health technologies.  Aquavit's business approach is enhanced by valuable global alliances.  Aquavit is developing an innovative drug delivery system that personalizes pharmaceutical solutions based on individual needs.  The company is based in New York City and Seoul.

About Accelrys Software, Inc.Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves.  The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development.  By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries.  Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists.  For more information about Accelrys, visit www.accelrys.com.

SOURCE Aquavit Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,063.99 -34.46 -0.20%
S&P 500 2,003.12 -0.25 -0.01%
NASDAQ 4,587.0320 +6.7610 0.15%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs